Multistep scheme for testing immunomodulatory substances. 1989

A Macela, and H Kovárová, and J Stulík, and M Ferencík, and P Propper, and E Hosková

The presented multistep program for testing immunomodulatory properties of biological response modifiers offers the possibility to evaluate multilaterally the modulatory potential of the tested preparations and to obtain basic data concerning their acute immunotoxicity. The scheme is divided into four stages: screening, optimalization, modelling, and analytical stage, each of which can be carried out separately on a relatively individual basis. This division considers the effect of the preparation on basic functions of the cells participating in the network of immunoregulation, the influence on the course of the immune response, modulation of the reactivity of the immune system affected by a 'non-immunological' phenomenon, as well as changes in protein repertoire produced by different systems of cells exposed to the tested preparation and/or the immunogenic signal. Detailed toxicological evaluation should be performed separately from immunopharmacological evaluation, keeping in mind differences in the application of the substances and the animal model involved. Incorporation of mathematical modelling and computer analysis of the results obtained by using the scheme may prove valuable in solving problems associated with potential modulation of the host immune system in clinically significant situations.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

A Macela, and H Kovárová, and J Stulík, and M Ferencík, and P Propper, and E Hosková
September 2023, JAMA,
A Macela, and H Kovárová, and J Stulík, and M Ferencík, and P Propper, and E Hosková
October 1991, Journal of investigational allergology & clinical immunology,
A Macela, and H Kovárová, and J Stulík, and M Ferencík, and P Propper, and E Hosková
February 2011, Journal of biomedical nanotechnology,
A Macela, and H Kovárová, and J Stulík, and M Ferencík, and P Propper, and E Hosková
August 2021, Biometrical journal. Biometrische Zeitschrift,
A Macela, and H Kovárová, and J Stulík, and M Ferencík, and P Propper, and E Hosková
March 2000, BMJ (Clinical research ed.),
A Macela, and H Kovárová, and J Stulík, and M Ferencík, and P Propper, and E Hosková
June 1987, Tijdschrift voor diergeneeskunde,
A Macela, and H Kovárová, and J Stulík, and M Ferencík, and P Propper, and E Hosková
November 1995, Kidney international,
A Macela, and H Kovárová, and J Stulík, and M Ferencík, and P Propper, and E Hosková
January 1995, Contributions to nephrology,
A Macela, and H Kovárová, and J Stulík, and M Ferencík, and P Propper, and E Hosková
January 2012, Toxicologic pathology,
A Macela, and H Kovárová, and J Stulík, and M Ferencík, and P Propper, and E Hosková
November 1956, Pharmaceutisch weekblad,
Copied contents to your clipboard!